Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold

Journal of Medicinal Chemistry

Volumn 58, Issue 6, 2015, Pages 2649-2657

  Stefek, Milan ^a   Soltesova Prnova, Marta ^a   Majekova, Magdalena ^a   Rechlin, Chris ^b   Heine, Andreas ^b   Klebe, Gerhard ^b  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 MERCAPTO 5H 1,2,4 TRIAZINO[5,6 B]INDOLE 5 ACETIC ACID; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CARBOXYL GROUP; EPALRESTAT; INDOLE DERIVATIVE; METHYL GROUP; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID; ZOPOLRESTAT; ACETIC ACID; AKR1B1 PROTEIN, HUMAN; ENZYME INHIBITOR; SORBITOL;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; IC50; ISOTHERMAL TITRATION CALORIMETRY; MALE; NONHUMAN; PHYSICOCHEMICAL MODEL; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HUMAN; LENS; METABOLISM; WISTAR RAT; X RAY CRYSTALLOGRAPHY;

ACETIC ACID; ALDEHYDE REDUCTASE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; INDOLES; LENS, CRYSTALLINE; MALE; MODELS, MOLECULAR; RATS; RATS, WISTAR; SORBITOL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925957194     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5015814     Document Type: Article

References (51)

1. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications Pharmacol. Rev. 1998, 50, 21-33
2. Srivastava, S. K.; Ramana, K. V.; Bhatnagar, A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options Endocr. Rev. 2005, 26, 380-392
3. Ramana, K. V. Aldose reductase: new insights for an old enzyme Biomol Concepts 2011, 2, 103-114
4. Ramana, K. V.; Srivastava, S. K. Aldose reductase: a novel therapeutic target for inflammatory pathologies Int. J. Biochem. Cell Biol. 2010, 42, 17-20
5. Maccari, R.; Ottana, R. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions. J. Med. Chem. 2014, DOI: 10.1021/jm500907a (Perspective).
6. Sotriffer, C. A.; Kramer, O.; Klebe, G. Probing flexibility and induced-fit phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations Proteins, Structure, Function, and Bioinformatics 2004, 56, 52-66
7. Biadene, M.; Hazemann, I.; Cousido, A.; Ginell, S.; Joachimiak, A.; Sheldrick, G. M.; Podjarny, A.; Schneider, T. R. The atomic resolution structure of human aldose reductase reveals that rearrangement of a bound ligand allows the opening of the safety-belt loop Acta Crystallogr. D Biol. Crystallogr. 2007, 63 (Pt 6) 665-672
8. Howard, E. I.; Sanishvili, R.; Cachau, R. E.; Mitschler, A.; Chevrier, B.; Barth, P.; Lamour, V.; Van Zandt, M.; Sibley, E.; Bon, C.; Moras, D.; Schneider, T. R.; Joachimiak, A.; Podjarny, A. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A Proteins 2004, 55, 792-804
9. Hotta, N. New approaches for treatment in diabetes: aldose reductase inhibitors Biomed. Pharmacother. 1995, 5, 244-250
10. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Barlocco, D. Pharmacological approaches to the treatment of diabetic complications Expert Opin Ther Pat 2000, 10, 1245-1262
11. Miyamoto, S. Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications Expert Opin Ther Pat 2002, 12, 621-631
12. Chatzopoulou, M.; Pegklidou, K.; Papastavrou, N.; Demopoulos, V. J. Development of aldose reductase inhibitors for the treatment of inflammatory disorders Expert Opin Drug Discov 2013, 8, 1365-1380
13. Alexiou, P.; Pegklidou, K.; Chatzopoulou, M.; Nicolaou, I.; Demopoulos, V. J. Aldose reductase enzyme and its implication to major health problems of the 21(st) century Curr. Med. Chem. 2009, 16, 734-752
14. Chatzopoulou, M.; Alexiou, P.; Kotsampasakou, E.; Demopoulos, V. J. Novel aldose reductase inhibitors: a patent survey (2006-present) Expert Opin Ther Pat 2012, 11, 1303-1323
15. Del-Corso, A.; Balestri, F.; Di Bugno, E.; Moschini, R.; Cappiello, M.; Sartini, S.; La-Motta, C.; Da-Settimo, F.; Mura, U. A new approach to control the enigmatic activity of aldose reductase PLoS One 2013, 8 (9) e74076
16. Cappiello, M.; Moschini, R.; Balestri, F.; Mura, U.; Del-Corso, A. Basic models for differential inhibition of enzymes Biochem. Biophys. Res. Commun. 2014, 445 (3) 556-560
17. Jones, M. L.; Gunn, D.; Johnes, J. H.; Van Zandt, M. C. Substituted indolealkanoic acids. International Patent Application WO/1999/50268 A2, Oct. 7, 1999; The Institutes for Pharmaceutical Discovery, Inc. (assignee).
18. Van Zandt, M. C.; Jones, M. L.; Gunn, D. E.; Geraci, L. S.; Jones, J. H.; Sawicki, D. R.; Sredy, J.; Jacot, J. L.; Dicioccio, A. T.; Petrova, T.; Mitschler, A.; Podjarny, A. D. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications J. Med. Chem. 2005, 48 (9) 3141-3152
19. Van Zandt, M. C.; Doan, B.; Sawicki, D. R.; Sredy, J.; Podjarny, A. D. Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications Bioorg. Med. Chem. Lett. 2009, 19 (7) 2006-2008
20. Toyooka, N.; Kato, A.; Adachi, I. Preparation of fused tricyclic compounds as aldose reductase inhibitors. WO2009078423A1, 2009; National University Corp., University of Toyama, Japan.
21. Luker, T.; Bonnert, R.; Brough, S.; Cook, A. R.; Dickinson, M. R.; Dougall, I.; Logan, C.; Mohammed, R. T.; Paine, S.; Sanganee, H. J.; Sargent, C.; Schmidt, J. A.; Teague, S.; Thom, S. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981 Bioorg. Med. Chem. Lett. 2011, 21 (21) 6288-6292
22. Chung, S.; LaMendola, J. Cloning and sequence determination of human placental aldose reductase gene J. Biol. Chem. 1989, 264, 14775-14777
23. Gui, T.; Tanimoto, T.; Kokai, Y.; Nishimura, C. Presence of a closely related subgroup in the aldose-ketoreductase family of the mouse Eur. J. Biochem. 1995, 227, 448-453
24. El-Kabbani, O.; Wilson, D. K.; Petrash, J. M.; Quiocho, F. A. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites Mol. Vis. 1998, 4, 19-25
25. Marvin, version 14.7.21.0; ChemAxon: Budapest, Hungary, 2014; http://www.chemaxon.com.
26. Steuber, H.; Heine, A.; Podjarny, A.; Klebe, G. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features J. Mol. Biol. 2008, 379, 991-1016
27. Steuber, H.; Czodrowski, P.; Sotriffer, P.; Klebe, G. Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase J. Mol. Biol. 2007, 373, 1305-1320
28. Dullweber, F.; Stubbs, M. T.; Musil, D.; Sturzebecher, J.; Klebe, G. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition J. Mol. Biol. 2001, 313, 593-614
29. Fukada, H.; Takahashi, K. Enthalpy and heat capacity changes for the proton dissociation of various buffer components in 0.1 M potassium chloride Proteins, Structure, Function, and Genetics 1998, 33, 159-166
30. ACD/ChemSketch, version 2013-11-07; Advanced Chemistry Development, Inc.: Toronto, Ontario, Canada, 2014; www.acdlabs.com.
31. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
32. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties drug candidates Nat. Rev. Drug Discov 2009, 8, 203-212
33. Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 2010, 53, 2986-2997
34. Terashima, H.; Hama, K.; Yamamoto, R.; Tsuboshima, M.; Kikkawa, R.; Hatanaka, I.; Shigeta, Y. Effects of a new aldose reductase inhibitor on various tissues in vitro J. Pharmacol. Exp. Ther. 1984, 229, 226-230
35. Chambers, C. C.; Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. Model for aqueous solvation based on class IV atomic charges and first solvation shell effects J. Phys. Chem. 1996, 100, 16385-16398
36. Lamour, V.; Barth, P.; Rogniaux, H.; Poterszman, A.; Howard, E.; Mitschler, A.; VanDorsselaer, A.; Podjarny, A.; Moras, D. Production of crystals of human aldose reductase with very high resolution diffraction Acta Crystallogr. D Biol. Crystallogr. 1999, 55 (Pt 3) 721-723
37. Mueller, U.; Darowski, N.; Fuchs, M. R.; Forster, R.; Hellmig, M.; Paithankar, K. S.; Puhringer, S.; Steffien, M.; Zocher, G.; Weiss, M. S. Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin J. Synchrotron Radiat 2012, 19 (Pt 3) 442-449
38. Otwinowski, Z.; Minor, W. Processing of x-ray diffraction data collected in oscillation mode Meth. Enzymol. 1997, 276, 307-326
39. Steuber, H.; Zentgraf, M.; Gerlach, C.; Sotriffer, C. A.; Heine, A.; Klebe, G. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions J. Mol. Biol. 2006, 363, 174-187
40. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
41. Collaborative computational project number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 1994, 50 (Pt 5) 760-763
42. Emsely, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 2004, 60 (Pt 12) 2126-2132
43. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 2010, 66 (2) 213-221
44. MOE, version 2012; Chemical Computing Group: Montreal, Quebec, Canada.
45. SYBYL-X, version 2.0; Tripos International: St. Louis, MO, U.S.
46. Chen, V. B.; Arendall, W. B., III; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr. D Biol. Crystallogr. 2010, 66 (Pt 1) 12-21
47. Sheldrick, G. M.; Schneider, T. R. SHELXL: high-resolution refinement Meth. Enzymol. 1997, 277, 319-343
48. Keller, S.; Vargas, C.; Zhao, H.; Piszczek, G.; Brautigam, C. A.; Schuck, P. High-precision isothermal titration calorimetry with automated peak-shape analysis Anal. Chem. 2012, 84, 5066-5073
49. Houtman, J. C.; Brown, P. H.; Bowden, B.; Yamaguchi, H.; Appella, E.; Samelson, L. E. Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling Protein Sci. 2007, 16, 30-42
50. Schuck, P. https://sedfitsedphat.nibib.nih.gov/software/default.aspx (accessed July 17, 2014).
51. GUSSI, version 1.0.5k; The University of Texas Southwestern Medical Center: Dallas, TX.